::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

THE STUDY OF PULMONARY HYPERTENSION PREVALENCE IN PATIENTS OF COPD

AUTHORS:

1Mr. Agha Amir Mohsin Khan, 2Syed Ali Anzar Naveed, 3Yaqoob Hussain

ABSTRACT:

Objective: The main objective of this research was to establish the prevalence of pulmonary hypertension in patients with a history of chronic obstructive pulmonary disease. Place and duration of study: This research was carried out in a period of 15 months from December 2019 to February 2020 in Nishtar Hospital, Multan. Material and Methods: For this study, a total of 100 patients were chosen. This research included both male and female genders with an age greater than 30 years and a history of COPD greater than one year. This research excluded patients who had a previous history of connective tissue disorders, primary pulmonary hypertension, and chronic pulmonary edoema. These patients were classified as COPD with a FEV1/FVC ratio of less than 0.70 on the basis of a pulmonary function test and an improvement in FEV1 of less than 12% after bronchodilator therapy. COPD GOLD recommendations were used and patients were split into various groups, and our research included patients with serious and moderate categories. To assess pulmonary artery pressure, transthoracic echocardiography was used and pulmonary hypertension was labelled as a pressure greater than 25mmHg. Results:Our analysis included a total of 100 patients with COPD. The mean age was61.21±12.79. Among the 81 patients, all had a history of smoking and were male. In 51 percent of patients, a severe form of COPD was seen. In 40 percent of the patients, pulmonary hypertension was seen. No major difference in gender was seen (P value 0.54). Patients with a history of COPD that has been seen in 36 (53.73 percent of patients for more than 5 years had a substantial p-value of p=0.001. In 23 (57.50 percent) of the patients who have extreme COPD, a similarly high p-value p=0.04 was seen. Conclusion: About half of the patients with COPD experienced pulmonary hypertension and this number was higher over more than 5 years in patients with a history of serious COPD. Conclusion: Children with β thalassemia major can also suffer from hypothyroidism even in the absence of signs and symptoms. It is also absolutely important to routinely screen children with beta thalassemia for hypothyroidism in order to allow an early diagnosis and provide rapid care. Keywords: Chronic Obstructive, Hypertension, Pulmonary Disease.